CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control

Drug Metabolism and Drug Interactions

Volumn 28, Issue 1, 2013, Pages 59-63

  Kitzmiller, Joseph Paul ^a   Sullivan, Danielle M ^a   Phelps, Mitchell A ^a   Wang, Danxin ^a   Sadee, Wolfgang ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

CYP3A4 5 combined genotype; Gene gene interaction; Pharmacogenomics; Statin

Indexed keywords

ATORVASTATIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; LIPID; MEVINOLIN; SIMVASTATIN;

ADULT; AGED; ALLELE; ARTICLE; COMPARATIVE STUDY; DOSE CALCULATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE;

AGED; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MIDDLE AGED; PYRROLES; SIMVASTATIN;

EID: 84876551991     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0031     Document Type: Article

References (17)

1. American Heart Association. Alert-cardiovascular disease costs 2011. Available at: http://www.americanheart.org. Accessed 31 October, 2012.
2. Kitzmiller JP, Groen DK, Phelps MA, Sadee W. Pharmacogenomic testing: relevance in medical practice. Cleve Clin J Med 2011;8:243-57.
3. Wilke RA, Reif DM, Moore JH. Combinatorial pharmacogenetics. Drug Discovery 2005;4:911-8.
4. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008;392:1093-108.
5. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008;38:1240-51.
6. Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J 2011;11:274-86.
7. Elens L, Becker ML, Haufroid V, Hofman A, Visser LE, Uitterlinden AG, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics 2011;21:861-6.
8. Elens L, van Schaik RH, Panin N, de Meyer M, Wallemacq P, Lison D, et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors'dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 2011;12:1383-96.
9. Elens L, Bouamar R, Hesselink DA, Haufroid V, van der Heiden IP, van Gelder T, et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin Chem 2011;57:1574-83.
10. Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C → T polymorphism (CYP3A4.*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-Treated kidney transplant patients. Pharmacogenet Genomics 2012;22:373-80.
11. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genom 2005;15:415-21.
12. Kim KA, Park PW, Lee OJ, Kang DK, Park JY. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007;47:87-93.
13. Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenomics 2004;14:523-5.
14. Shin J, Pauley DF, Pacanowski MA, Langaee T, Frye RF, Johnson JA. Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin. Pharmacotherapy 2011;31:942-50.
15. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, et al. CYP3A5.*3 allele is associated with reduced lipid-lowering response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008;398:15-20.
16. Feigenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78:551-8.
17. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:234-72.